OneAlphaMed combined expert-led roadshows, frictionless mobile data capture, and a gamified sales activation engine to build unparalleled clinical trust and accelerate Real-World Evidence generation.
Industry / Specialty
Pharmaceutical & Healthcare
Scale / Audience
15,000+ HCPs
Core Solutions
Co-created Certification
Time to Value
Pan-India Deployment
Stop funding clicks. Start building undisputed credibility for your brand today.
Launching a Real-World Evidence (RWE) study for a rare neurological disorder is notoriously slow. Eligible patients are scarce, specialist HCPs are over-committed, and internal sales teams lack the visibility and motivation to sustain enrollment momentum over months. OneAlphaMed shifted the strategy from passive digital invites to a highly active, expert-led ground game — supported by a live digital dashboard and gamified field-force activation — drastically accelerating the publication timeline. The result was 3X faster enrollment, 150+ active trial centers, and 1,200+ verified data points.
Finding eligible patients for rare disease trials requires massive, geographically dispersed HCP participation — and the traditional approach was failing on every front.
The eligible patient population for this rare neurological disorder was dispersed across hundreds of neurology clinics and general practices nationwide. Identifying and onboarding these patients required a level of coordinated, on-the-ground HCP engagement that no centralized digital campaign could achieve alone.
Neurologists and specialist physicians — already overwhelmed by their clinical caseloads — lacked the time and administrative infrastructure to participate in complex RWE data submission protocols. The burden of data entry was consistently cited as the primary reason for low trial center participation in preliminary outreach.
The pharmaceutical brand's internal sales and medical teams lacked real-time visibility into trial enrollment progress. Without a live dashboard, reps had no sense of competitive momentum or daily targets, making it nearly impossible to sustain the energy and focus required for a sustained multi-month enrollment drive.
OneAlphaMed deployed a multi-pronged strategy that simultaneously built clinical trust, removed administrative friction, and injected motivational energy into the field force.
Before a single patient was enrolled, OneAlphaMed organized a series of exclusive, KOL-led regional briefings across targeted neurology hubs. These intimate, peer-to-peer scientific sessions — featuring local opinion leaders rather than company representatives — built the localized clinical trust essential for persuading reluctant centers to commit to trial participation.
OneAlphaMed's medical technology team deployed an intuitive, mobile-first data entry system specifically designed for the neurology workflow. The tool reduced the per-patient data submission time by 60% compared to legacy paper-based methods, eliminating the primary barrier to HCP participation and allowing data to flow in real-time to the central study database.
A real-time analytics dashboard was launched for the brand's field force, displaying live regional enrollment counts, individual rep performance metrics, and competitive standings against national targets. This transparent, gamified approach created healthy internal competition, recognizing high performers and providing every team member with clear, daily targets.
Sales Gamification for Scientific Outcomes.
By transforming trial enrollment into a transparent, competitive, team-based effort — with real-time visibility for every stakeholder — OneAlphaMed completely bypassed the traditional sluggishness of RWE recruitment. The innovation was not simply technological; it was
The program shattered standard clinical trial timelines and generated hard credibility metrics that will anchor the brand's scientific narrative for years.
The RWE study generated far more than clinical data; it created a self-sustaining cycle of trust between the brand, its medical community, and its own internal commercial teams.
Gained the flexibility to engage with cutting-edge trial data on their own schedule without interrupting clinical hours. This led to a dramatic improvement in the depth and quality of scientific contributions, as experts contributed insights when mentally prepared rather than when logistically forced to attend.
Received highly structured, easily exportable qualitative feedback — organized by theme, region, and scientific sentiment — replacing the chaotic, unreliable transcripts from previous live sessions. The structured insights directly informed the brand's Phase IV strategy and label messaging.
Restored and deepened relationships with high-value scientific experts by visibly and demonstrably respecting their time. The asynchronous model also dramatically reduced the per-KOL engagement cost while simultaneously increasing the richness of the insights obtained.
The platform includes mandatory engagement checkpoints embedded throughout each module. KOLs must complete specific interactive elements — clinical data interpretation tasks, opinion-capture questions, and video response prompts — before unlocking subsequent sections. The system logs granular interaction data, including time spent on each slide, to validate genuine engagement.
Yes. The hub features enterprise-grade AES-256 encryption at rest and in transit, individual NDA-gated access paths, and a strict role-based permission system. Specific modules can be restricted to select KOLs based on their advisory agreement level, ensuring that data confidentiality is maintained across all geographies.
Honorarium disbursements are automatically triggered upon the verified completion of all mandatory engagement modules. The system generates a digital completion certificate and a timestamped activity log for each KOL, which feeds directly into our compliant honorarium processing workflow — ensuring seamless, fully-documented compensation.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.